Document is current
Any future updates will be listed below
-
Authors
Asaad, Eleonora https://orcid.org/0009-0002-2677-3266
Schobert, Julia https://orcid.org/0009-0004-9409-1018
Stubbe, Katharina
Erdur, Hebun
Hahn, Katrin https://orcid.org/0000-0002-6013-0072
Kleine, Justus F. https://orcid.org/0000-0002-2803-075X
-
Funding
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Received: 3 May 2024
Revised: 14 February 2025
Accepted: 2 March 2025
First Online: 18 March 2025
Declarations
:
: The study was approved by the local ethics committee of Charité Universitätsmedizin Berlin. The ethics approval number is EA1/242/20.
: All participants provided written informed consent.
: All participants provided consent for publication.
: Katrin Hahn received financial reimbursement for consulting, advisory board activities, speaker fees, and/or contributions to congresses and travel support to attend scientific meetings by Akcea Therapeuticals Inc., Alnylam Pharmaceuticals Inc., AstraZeneca, Takeda Pharmaceutical Inc., Pfizer Pharmaceuticals Inc., and Swedish Orphan Biovitrum Inc. KH further received research funding by the foundation Charité (BIH clinical fellow), Alnylam Pharmaceuticals Inc., and Pfizer Pharmaceuticals. None of this is related to the manuscript. Eleonora Asaad received financial reimbursement for travel support to attend scientific meetings by Amicus Therapeutics. This is not related to the manuscript. All other authors declare they have no conflict of interest.
